diseases-and-conditions

Is This MannKind's Greatest Risk?

Not long ago, some predicted that MannKind faced the serious risk of striking out on winning approval for Afrezza. Instead, those...

Is Pharmacyclics the Next Celgene?

Pharmacyclics has made a big move in the past two years as investors have become increasingly excited by the potential for Imbruvica,...

Why Agenus Inc. Stock Skyrocketed

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in...